Corticosteroids in Lupus Nephritis and Central Nervous System Lupus

Rheumatic Disease Clinics of North America

Volumn 42, Issue 1, 2016, Pages 63-73

  Kamen, Diane L ^a   Zollars, Eric S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Autoimmune disease; Glomerulonephritis; Glucocorticoids; Neuropsychiatric lupus; Systemic lupus erythematosus; Treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM LUPUS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEPRESSION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; GROWTH DISORDER; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOMANIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INDUCTION CHEMOTHERAPY; INFECTION; KIDNEY BIOPSY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MENTAL DISEASE; OSTEOPOROSIS; PLASMAPHERESIS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; LUPUS NEPHRITIS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; SEVERITY OF ILLNESS INDEX;

ADRENAL CORTEX HORMONES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; SEVERITY OF ILLNESS INDEX;

EID: 84961247151     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.08.008     Document Type: Review

References (46)

1. Tucker L.B., Menon S., Schaller J.G., et al. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 1995, 34:866-872.
2. Bastian H.M., Roseman J.M., McGwin G., et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002, 11:152-160.
3. Brunner H.I., Gladman D.D., Ibanez D., et al. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008, 58:556-562.
4. Lim S.S., Bayakly A.R., Helmick C.G., et al. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the Georgia Lupus Registry. Arthritis Rheumatol 2014, 66:357-368.
5. Somers E.C., Marder W., Cagnoli P., et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan lupus epidemiology and surveillance program. Arthritis Rheumatol 2014, 66:369-378.
6. Korbet S.M., Schwartz M.M., Evans J., et al. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007, 18:244-254.
7. Faurschou M., Dreyer L., Kamper A.L., et al. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken) 2010, 62:873-880.
8. Costenbader K.H., Desai A., Alarcon G.S., et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011, 63:1681-1688.
9. Ward M.M. Recent clinical trials in lupus nephritis. Rheum Dis Clin North Am 2014, 40:519-535. ix.
10. Houssiau F.A. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther 2012, 14:202.
11. Felson D.T., Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984, 311:1528-1533.
12. Boumpas D.T., Austin H.A., Vaughn E.M., et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992, 340:741-745.
13. Illei G.G., Austin H.A., Crane M., et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001, 135:248-257.
14. Houssiau F.A., Vasconcelos C., D'Cruz D., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46:2121-2131.
15. Ginzler E.M., Dooley M.A., Aranow C., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353:2219-2228.
16. Appel G.B., Contreras G., Dooley M.A., et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20:1103-1112.
17. Hahn B.H., McMahon M.A., Wilkinson A., et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012, 64:797-808.
18. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. Chapter 12: Lupus Nephritis. Kidney Int Suppl 2012, 2:221-232.
19. Kirou K.A., Boumpas D.T. Systemic glucocorticoid therapy in SLE. Dubois' lupus erythematosus 2013, 591-600. Lippincott Williams & Wilkins, Philadelphia. 8th edition. D.J. Wallace, B.H. Hahn (Eds.).
20. Isenberg D., Appel G.B., Contreras G., et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010, 49:128-140.
21. Dooley M.A., Jayne D., Ginzler E.M., et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011, 365:1886-1895.
22. Houssiau F.A., D'Cruz D., Sangle S., et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010, 69:2083-2089.
23. Condon M.B., Ashby D., Pepper R.J., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013, 72:1280-1286.
24. Lightstone L. Minimising steroids in lupus nephritis-will B cell depletion pave the way?. Lupus 2013, 22:390-399.
25. Fanouriakis A., Boumpas D.T., Bertsias G.K. Pathogenesis and treatment of CNS lupus. Curr Opin Rheumatol 2013, 25:577-583.
26. Hanly J.G., Urowitz M.B., Su L., et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010, 69:529-535.
27. Wang Z., Wang Y., Zhu R., et al. Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies. Medicine (Baltimore) 2015, 94:e794.
28. Bertsias G.K., Ioannidis J.P., Aringer M., et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69:2074-2082.
29. Singer J., Denburg J.A. Diagnostic criteria for neuropsychiatric systemic lupus erythematosus: the results of a consensus meeting. The Ad Hoc Neuropsychiatric Lupus Workshop Group. J Rheumatol 1990, 17:1397-1402.
30. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42:599-608.
31. Nishimura K., Omori M., Katsumata Y., et al. Neurocognitive impairment in corticosteroid-naive patients with active systemic lupus erythematosus: a prospective study. J Rheumatol 2015, 42:441-448.
32. Kremer J.M., Rynes R.I., Bartholomew L.E., et al. Non-organic non-psychotic psychopathology (NONPP) in patients with systemic lupus erythematosus. Semin Arthritis Rheum 1981, 11:182-189.
33. Ainiala H., Loukkola J., Peltola J., et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001, 57:496-500.
34. Mitsikostas D.D., Sfikakis P.P., Goadsby P.J. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 2004, 127:1200-1209.
35. Hanly J.G., Urowitz M.B., O'Keeffe A.G., et al. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum 2013, 65:2887-2897.
36. Unterman A., Nolte J.E., Boaz M., et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 2011, 41:1-11.
37. Bhangle S.D., Kramer N., Rosenstein E.D. Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int 2013, 33:1923-1932.
38. Andrade R.M., Alarcon G.S., Gonzalez L.A., et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis 2008, 67:829-834.
39. Hanly J.G., Urowitz M.B., Su L., et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis 2012, 71:1502-1509.
40. West S.G. Clinical aspects of the nervous system. Systemic glucocorticoid therapy in SLE 2013, 368-381. Lippincott Williams & Wilkins, Philadelphia. 8th edition. D.J. Wallace, B.H. Hahn (Eds.).
41. Pego-Reigosa J.M., Isenberg D.A. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford) 2008, 47:1498-1502.
42. Ramos-Casals M., Soto M.J., Cuadrado M.J., et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009, 18:767-776.
43. Sanna G., Bertolaccini M.L., Khamashta M.A. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des 2008, 14:1261-1269.
44. Sergent J.S., Lockshin M.D., Klempner M.S., et al. Central nervous system disease in systemic lupus erythematosus. Therapy and prognosis. Am J Med 1975, 58:644-654.
45. Petri M., Spence D., Bone L.R., et al. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992, 71:291-302.
46. Bultink I.E., Harvey N.C., Lalmohamed A., et al. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int 2014, 25:1275-1283.